Advertisement
Advertisement
U.S. markets open in 9 hours 5 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Neoleukin Therapeutics, Inc. (NLTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.11000.0000 (0.00%)
At close: 04:00PM EDT
1.0900 -0.02 (-1.80%)
After hours: 07:57PM EDT
Advertisement

Neoleukin Therapeutics, Inc.

188 East Blaine Street
Suite 450
Seattle, WA 98102
United States
855 226 6447
https://www.neoleukin.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees79

Key Executives

NameTitlePayExercisedYear Born
Dr. Jonathan G. Drachman M.D.CEO, Pres, Principal Financial Officer & Director651.29kN/A1962
Dr. Priti Patel M.D., M.S.Chief Medical Officer512.73kN/A1976
Dr. David BakerCo-founder & Member of Scientific Advisory BoardN/AN/AN/A
Mr. Sean Michael SmithPrincipal Accounting Officer, VP of Fin. & ControllerN/AN/A1986
Ms. Donna M. Cochener-Metcalfe J.D.Gen. Counsel & Sr. VP of LegalN/AN/A1975
Dr. Carl Walkey Ph.D.Sr. VP of Corp. Devel.N/AN/A1985
Ms. Samantha WillingSr. VP of People & CultureN/AN/AN/A
Mr. Kamran AlamSr. Strategic AdvisorN/AN/A1974
Dr. Bill ArthurVP & Head of ResearchN/AN/AN/A
Mr. Umut UlgeVP of Clinical Devel.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Corporate Governance

Neoleukin Therapeutics, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 7. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement